contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-enters-middle-east-collaboration

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Nightingale Health

Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company's Remote Health Check in a full-scale commercial operation for Enigma's clients in Saudi Arabia and the wider MENA region. 

Translation: Original published in Finnish on 1/27/2025 at 12:26 noon EET.
Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company&apos;s Remote Health Check in a full-scale commercial operation for Enigma&apos;s clients in Saudi Arabia and the wider MENA region. The cooperation is a four-stage process: pilot, launch, sales expansion and full-scale commercial adoption. According to the company, preparations for the pilot phase will begin in early 2025, which could mean as soon as the next few weeks.
<h2>The service is a logical addition to Enigma&apos;s offering</h2>
According to the press release, Enigma aims to be a leader in personalized medicine in Saudi Arabia and the Middle East, transforming healthcare by providing AI-powered genetic analysis for diagnostics and research. Enigma provides genetic analysis directly to consumers and healthcare providers. Nightingale&apos;s blood analysis is, in our view, a logical complement to this offering, providing Enigma with a one-time genetic analysis service for sale alongside a recurring analysis of the impact of lifestyle and lifestyle changes on disease risk.
<h2>Only time will tell the commercial scale of the cooperation</h2>
The press release did not estimate the revenue impact of the collaboration. The use case for the service looks like a combination of individual test orders (we see lower potential) and possible routine use in health checks (higher potential), so its commercial significance will only become clear over time as the service gains traction. We estimate that, if successful, the collaboration will take at least one year to ramp, with the revenue impact of the agreement beginning in fiscal 2026 or 2027. Our forecasts already include significant revenue growth for the next few years, so this news does not put immediate pressure on them. Currently, the main forecast risks relate to the pace of progress of the numerous joint ventures Nightingale has won and their achievable commercial scale. In any case, the release supports our forecasts and is a further indication of the attractiveness of the company&apos;s service in the global healthcare diagnostics market. The partnership marks Nightingale&apos;s first entry into the clinical segment in the MENA region.

Inderes

Nightingale Health enters Middle East collaboration

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Valuation methods: DCF model

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.

The DuPont formula helps understand the dynamics of value creation

	2024	25e	26e
Omsætning	4,4	6,5	10,8
vækst-%	4,21 %	50,10 %	65,10 %
EBIT (adj.)	-18,6	-17,9	-15,5
EBIT-% (adj.)	-426,62 %	-273,48 %	-143,18 %
EPS (adj.)	-0,29	-0,28	-0,23
Udbytte	0,00	0,00	0,00
Udbytte %
P/E (adj.)	-	-	-
EV/EBITDA	-	-	-

Nightingale Health enters Middle East collaboration

The service is a logical addition to Enigma's offering

Only time will tell the commercial scale of the cooperation

Nightingale Health

Key Estimate Figures23.09.2024